Imaging Endpoints II

Imaging Endpoints II is a leading, oncology-focused imaging contract research organization (iCRO) that provides end-to-end imaging services for clinical trials, from early-stage design to late-stage analysis and regulatory support. The company leverages a deep scientific team and proprietary technologies, including its 'Deep Imaging' program featuring radiomics and AI, to customize imaging endpoints and improve the probability of trial success. Headquartered in Scottsdale, Arizona, it is a private, revenue-generating services company that has contributed to numerous oncology drug approvals and supports a global client base of pharmaceutical and biotech sponsors.

Centralized imaging core lab with a proprietary 'Deep Imaging' program. This program utilizes advanced imaging acquisition techniques and post-processing technologies, including Artificial Intelligence (AI) and Radiomics, to extract quantitative biomarkers and optimize imaging analysis for oncology clinical trials.

Operates in the competitive imaging CRO (iCRO) segment, competing against both specialized iCROs (e.g., BioClinica, now part of Labcorp) and the large, diversified global CROs (e.g., IQVIA, Parexel, ICON) that have imaging divisions. Its key differentiator is its exclusive focus on oncology and its investment in advanced, AI-powered imaging analytics.